You are currently browsing the tag archive for the ‘BI’ tag.

How can we monitor Dabigatran effects ?

Dabigatran, like argatroban, does prolong the prothrombin time (PT) and partial thromboplastin time (PTT). It also prolongs the thrombin time (TT), which means it  generates a false decrease in fibrinogen assay results, given that the fibrinogen assay is based on the TT. Dabigatran’s plasma concentration peaks about two hours after the drug is taken, and its half-life is 12 to 17 hours, so the PT, PTT, and fibrinogen assays should be made at least 24 hours after discontinuing dabigatran. Biophen’s Hemoclot Thrombin Inhibitor allows exploration of all the direct anti-thrombin inhibitors (DTI), targeted to human thrombin.

and the winner is…. I extrapolated 220.000 € to Spanish projects while                                100.000 to Italy, Romania, Belg…

Paris, France and Ingelheim, Germany, 29th August 2011 – Last night at an award ceremony in Paris, the 32 winning projects of the global disease awareness initiative 1 Mission 1 Million – Getting to the Heart of Stroke were announced. The projects were chosen by the public and a panel of experts. They will be awarded a share of the €1 million donation to fulfil the overall mission of preventing as many as one million atrial fibrillation (AF)-related strokes through awareness campaigns. 1 Mission 1 Million is supported by over 45 third-party organisations around the world and is sponsored by Boehringer Ingelheim.

finally the expert panel delivered the list of projects for step 2.

Public vote will start, if the schedule will not change, after march 22nd.

https://www.heartofstroke.com/1-mission-1-million

our project passed the screening of the experts see at the link provided not yet activated by the system

https://www.heartofstroke.com/spaces

 

on 30 August 2010

Ingelheim, Germany – Report: The European Society of Cardiology (ESC) today issued a revised version of  guidelines for the management of atrial fibrillation (AF), including guidance on the role of thge new oral treatment, dabigatran etexilate, for the prevention of embolism in patients with atrial fibrillation (AF).

At the same time, Boehringer Ingelheim confirms that Food and Drug Administration (FDA) granted a priority review designation for Boehringer Ingelheim’s novel oral direct thrombin inhibitor (DTI) dabigatran etexilate for the prevention of stroke in AF. A priority review designation is given to new drugs that are expected to offer large advances in treatment, or provide a treatment where no adequate therapy exists. An FDA advisory committee will meet on Monday, September 20th, to review and discuss dabigatran etexilate data.

In addition to the US, the registration process for dabigatran etexilate is underway in EU, Japan and other countries. The company expects to receive a marketing authorization for dabigatran etexilate in first countries by end of 2010 or beginning of 2011. The drug availability was expected according to many opinions in fall winter 2010. Similar molecules are expected also by other companies. For people with AF, it is the first competitor to warfarin that is likely to be marketed for stroke prevention, although caution is still urged by reviewers. Stay tuned….

What is 1 Mission 1 Million?

1 Mission 1 Million is a new global campaign to raise awareness of atrial fibrillation and its link to stroke.  €1 million is available to fund community-driven projects, chosen by you, that take action against atrial fibrillation-related stroke by contributing to this goal.  Play your part by submitting a project you need funding for.

Up to three million people worldwide have a stroke related to atrial fibrillation every year – that is one person every 12 seconds.1,2,3 Many people do not understand what atrial fibrillation is, its link to stroke or that many of these strokes could be prevented.4 1 Mission 1 Million aims to address this.